Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1

Conditions

Sarcoma 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 1282Specimen Handling 927Carboplatin 836Magnetic Resonance Spectroscopy 834Cyclophosphamide 807Cisplatin 735Nivolumab 680Paclitaxel 635Radiotherapy 617Gemcitabine 580Biopsy 559Bevacizumab 485Dexamethasone 444fludarabine 410Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 361Fluorouracil 357atezolizumab 350durvalumab 340Rituximab 335Drug Therapy 333Radiosurgery 321Doxorubicin 319Blood Specimen Collection 317Standard of Care 311Pemetrexed 307Ipilimumab 303Radiation 287

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
EBC-46 × 1 year × Clear all
NCT05755113 2026-03-12

A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma

QBiotics Group Limited

Phase 2 Recruiting
40 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma

NCT05608876 2025-08-07

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

QBiotics Group Limited

Phase 2 Active not recruiting
15 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡